Statistical innovations have dramatically transformed oncology trials in recent years. One of the key advancements is the development of adaptive trial designs, which allow modifications to be made as the trial progresses. This flexibility enables researchers to make real-time adjustments, optimizing the trial without exposing patients to unnecessary risks. Such designs are particularly valuable in oncology, where patient responses to treatment can vary widely.